Amir Jazaeri

Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays.

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.

BRCA1-mediated repression of select X chromosome genes.

The utility of HPV DNA triage in the management of cytological AGC.

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.

Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.

Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.

Cervical adenocarcinoma in situ: the predictive value of conization margin status.

Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.

A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma.

Cyclooxygenase-2 in cervical neoplasia: a review.

Utilization of a uniform grading system for interpreting serous ovarian cancer.

Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.

A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.

The promise of antiangiogenic therapy for ovarian cancer.

CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis.

Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.

Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.

The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts.

Appendiceal pathology at the time of oophorectomy for ovarian neoplasms.

A nomogram for estimating the probability of ovarian cancer.

Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Frailty: an outcome predictor for elderly gynecologic oncology patients.

Summary of the 2012 American Association for Cancer Research (AACR) Annual Meeting.

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.

Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era.

Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.